Risk for Mortality in High versus Low Antiparkinsonian Therapy Dose During the First Year of Parkinson's Disease: A Real-World Study.
Yael BarerOlga Sánchez-SoliñoGabriel ChodickMeital Grabarnik-JohnShiran Naftelberg BlonderNeta Li Feurestein-GanorLars BergmannConnie H YanSivan GazitDavid ArkadirPublished in: Advances in therapy (2024)
In PD, higher LEDD can be an early risk marker of increased mortality, probably because it reflects more severe disease.